Johnson & Johnson (JNJ) To Go Ex-Dividend on August 25th

Johnson & Johnson (NYSE:JNJ) declared a quarterly dividend on Wednesday, July 15th. Shareholders of record on Tuesday, August 25th will be given a dividend of 1.34 per share on Tuesday, September 8th. This represents a c) annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th.

Johnson & Johnson has increased its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 64 consecutive years. Johnson & Johnson has a dividend payout ratio of 48.3% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Johnson & Johnson to earn $12.67 per share next year, which means the company should continue to be able to cover its $5.36 annual dividend with an expected future payout ratio of 42.3%.

Johnson & Johnson Price Performance

Shares of JNJ opened at $249.70 on Friday. The company’s 50-day moving average is $239.19 and its 200-day moving average is $234.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market capitalization of $601.08 billion, a PE ratio of 28.93, a PEG ratio of 2.34 and a beta of 0.24. Johnson & Johnson has a fifty-two week low of $162.30 and a fifty-two week high of $269.43.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. Johnson & Johnson’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts forecast that Johnson & Johnson will post 11.67 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on JNJ. Raymond James Financial upped their target price on Johnson & Johnson from $258.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday. TD Cowen lifted their price target on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday. Guggenheim upped their price objective on Johnson & Johnson from $266.00 to $270.00 and gave the company a “buy” rating in a report on Friday, June 26th. Scotiabank reiterated an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a research report on Thursday. Finally, Bank of America lifted their target price on Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a report on Friday, July 10th. Nineteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $265.30.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.